Schizophrenia affects 1% of the global population and is caused by a complex interplay between at least 280 genes and ...
US-based biopharmaceutical company Spinogenix has concluded the enrolment of patients in its Phase II clinical trial of tazbentetol (previously known as SPG302), a synaptic regenerative treatment for ...
Patients with schizophrenia have a lot of life-changing consequences when they are being treated properly, and these are only amplified when the patient goes untreated, explained Megan Ehret, PharmD, ...
MedPage Today on MSN
Nursing homes falsely diagnose patients as schizophrenic to sedate them, report says
Dementia patients are given antipsychotics, which FDA warns may increase the risk for deat ...
In the months after 24-year-old D.J. was diagnosed with schizophrenia, he searched online for answers to questions that felt urgent and existential. Does it get really bad over time? Will I be able to ...
LB-102 has potential to be the first benzamide approved for schizophrenia in the U.S. NOVA-2 trial to enroll approximately ...
Bristol Myers Squibb (NYSE: BMY) today announced data from a Phase 4 clinical trial evaluating the symptom stability, safety and tolerability of Cobenfy (xanomeline and trospium chloride) when ...
One of the symptoms of schizophrenia is difficulty incorporating new information about the world. This can lead patients to ...
Researchers identified a protein biomarker linked to schizophrenia and developed a synthetic peptide that restores neural ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results